세계의 반려동물 의약품 시장 평가 : 동물 유형별, 적응증별, 투여 경로별, 유통경로별, 지역별, 기회, 예측(2018-2032년)

Companion animal pharmaceuticals market is projected to witness a CAGR of 9.15% during the forecast period 2025-2032, growing from USD 20.91 billion in 2024 to USD 42.14 billion in 2032. The market's growth is supported by the increasing adoption of companion animals, the introduction of supportive initiatives and policies globally, rising disposable incomes, increasing investments in veterinary pharmaceuticals, and growing availability of pet insurance

The market's growth is also supported by the increasing investments in technological innovations in veterinary diagnostic solutions. The introduction of advanced diagnostic solutions ensures the timely detection of various diseases, allowing pet owners to seek medical attention and therapeutic intervention for their pets in a time-efficient manner. As veterinary technologies evolve, the delivery of novel drug delivery systems and targeted therapies is increasing, ensuring improved disease management. The rising emphasis on innovation and research activities, coupled with growing awareness about companion animal health and the broader availability of pet insurance, is also bolstering the market's expansion.

New Product Investments Drive Growth Opportunities in the Market

Increasing investments in new launches are providing lucrative growth opportunities for the market by ensuring the availability of convenient, effective, and innovative products that support the evolving requirements of veterinarians and pet owners. Such launches often include advanced formulations, such as oral tick and flea treatments, as well as specialized therapeutics that target infectious and chronic diseases in pets. Additionally, rapid innovations in nutraceuticals, personalized medicines, and drug delivery systems are improving efficacy and adherence, ensuring wider adoption and positively influencing the market's expansion. Thus, various companies globally are focusing on launching products that facilitate easy adherence.

For instance, in April 2024, Boehringer Ingelheim International GmbH launched NexGard SPECTRA in India, following the approval by the Central Drugs Standard Control Organization (CDSCO). The soft chew provides a comprehensive range of external and internal parasite control in a single dose, administered monthly. The prescription-only product contains milbemycin oxime, which controls intestinal worms and provides protection against heartworm, as well as afoxolaner, which targets ticks and fleas.

Increasing Pet Insurance Boosts Global Companion Animal Pharmaceuticals Market Growth

As more pet owners are purchasing pet insurance, the financial barriers to pharmaceutical products for companion animals are being eliminated, resulting in increased demand for therapeutic and preventive purposes. Insurance coverage includes reimbursement for prescription medications, wellness visits, and management of chronic and infectious diseases, increasing accessibility for pet owners to high-quality and specialized pharmaceutical solutions.

As per the North America Pet Health Insurance Association, in 2024, the United States experienced a 12.7% growth in the total number of pets insured compared to 2023. With insurance, pet owners are more likely to seek timely veterinary intervention and adhere to prescribed treatment regimens, directly boosting demand for pharmaceuticals. Additionally, as the emotional bonds between pet owners and their companion animals increase, they are more likely to focus on their health and well-being, resulting in them providing their companion animals with regular check-ups and treatment interventions, which provide lucrative growth opportunities for the market.

Veterinary Hospitals and Clinics Hold Major Market Share

The segment's dominance can be attributed to the presence of advanced healthcare infrastructure, skilled professionals, and a comprehensive range of treatments and services across veterinary hospitals and clinics. Additionally, these facilities are equipped with advanced laboratory capabilities, surgical equipment, and diagnostic tools, allowing them to provide precise diagnoses and effectively treat a wide range of conditions in companion animals. The presence of skilled veterinarians ensures that pets receive specialized care, including the administration of pharmaceuticals, vaccinations, and preventive medications tailored to the specific requirements of companion animals. Thus, governments worldwide are increasingly funding veterinary hospitals and clinics to ensure that the animal population receives optimal care.

For instance, in May 2025, Oklahoma State University received USD 250 million in state funding to build a new veterinary hospital. Such investments are strengthening clinical capabilities, veterinary education, and research infrastructure, thereby propelling the demand for companion animal pharmaceuticals and positively influencing the market's expansion.

North America Dominates the Global Companion Animal Pharmaceuticals Market Growth

The market's rapid expansion in North America can be attributed to the rising adoption of companion animals in the region, the strong presence of leading market players, and high awareness about veterinary care practices and treatments. As per the estimates of the American Society for the Prevention of Cruelty to Animals (ASPCA), 4.2 million shelter animals were adopted in the United States in 2024. Furthermore, the region's rising innovations in companion animal medicines in the region, driven by the strong presence of various research organizations and institutions focused on veterinary care, are also providing lucrative growth opportunities for the market. Additionally, increasing consumer awareness about pet surgeries and various treatment solutions, coupled with the rising availability of pet insurance, is further bolstering the demand for pharmaceutical products for companion animals. Pet insurance plays a crucial role in helping pet owners manage pharmaceutical costs and other essential expenses that are vital for ensuring the health and well-being of their companion animals.

Impact of the U.S. Tariff on the Global Companion Animal Pharmaceuticals Market

The recently imposed tariffs are causing unrest in supply chains as the companion animal pharmaceuticals market relies heavily on international channels for sourcing the necessary raw materials, including biologics and antigens. Additionally, the growing threat of retaliatory tariffs is expected to result in reduced profit margins for the manufacturers and lead to additional operational uncertainties.

To mitigate the impact of the tariff, leading market players are focusing on shifting their supplier base; however, this shift is triggering an increased requirement for new regulatory filings and approvals, causing further disruptions in the supply chain.

Key Players Landscape and Outlook

Key players in the market are launching new products and technologies, engaging in mergers and acquisitions to expand their product portfolios and geographical presence, and increasing their revenue.

For instance, in September 2024, Elanco received approval from the US FDA for Zenrelia, an effective, safe, and convenient oral JAK inhibitor for controlling atopic dermatitis and pruritus associated with allergic dermatitis in dogs that are 12 months or older.

Additionally, the key players of the market are also engaging in mergers and acquisitions to support innovations in pet therapeutics. For instance, in January 2024, Ceva acquired Scout Bio, Inc., enhanced its biotechnology activities and developed preventive and biological medicines. Such acquisitions are also expected to bolster the development and availability of biotherapeutics for companion animals.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Companion Animal Pharmaceuticals Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Animal Type
    • 5.2.1.1. Dogs
    • 5.2.1.2. Cats
    • 5.2.1.3. Horses
    • 5.2.1.4. Others
  • 5.2.2. By Indication
    • 5.2.2.1. Infectious Disease
    • 5.2.2.2. Dermatologic Disease
    • 5.2.2.3. Parasitic Infection
    • 5.2.2.4. Orthopedic Disease
    • 5.2.2.5. Others
  • 5.2.3. By Route of Administration
    • 5.2.3.1. Oral
    • 5.2.3.2. Injectable
    • 5.2.3.3. Topical
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Veterinary Hospitals and Clinics
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Others
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Animal Type
  • 5.3.2. By Indication
  • 5.3.3. By Route of Administration
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Companion Animal Pharmaceuticals Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Animal Type
    • 6.2.1.1. Dogs
    • 6.2.1.2. Cats
    • 6.2.1.3. Horses
    • 6.2.1.4. Others
  • 6.2.2. By Indication
    • 6.2.2.1. Infectious Disease
    • 6.2.2.2. Dermatologic Disease
    • 6.2.2.3. Parasitic Infection
    • 6.2.2.4. Orthopedic Disease
    • 6.2.2.5. Others
  • 6.2.3. By Route of Administration
    • 6.2.3.1. Oral
    • 6.2.3.2. Injectable
    • 6.2.3.3. Topical
  • 6.2.4. By Distribution Channel
    • 6.2.4.1. Veterinary Hospitals and Clinics
    • 6.2.4.2. Retail Pharmacies
    • 6.2.4.3. Others
  • 6.2.5. By Country Share
    • 6.2.5.1. The United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Companion Animal Pharmaceuticals Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.1.1. Dogs
        • 6.3.1.2.1.2. Cats
        • 6.3.1.2.1.3. Horses
        • 6.3.1.2.1.4. Others
      • 6.3.1.2.2. By Indication
        • 6.3.1.2.2.1. Infectious Disease
        • 6.3.1.2.2.2. Dermatologic Disease
        • 6.3.1.2.2.3. Parasitic Infection
        • 6.3.1.2.2.4. Orthopedic Disease
        • 6.3.1.2.2.5. Others
      • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.3.1. Oral
        • 6.3.1.2.3.2. Injectable
        • 6.3.1.2.3.3. Topical
      • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.4.1. Veterinary Hospitals and Clinics
        • 6.3.1.2.4.2. Retail Pharmacies
        • 6.3.1.2.4.3. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Companion Animal Pharmaceuticals Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Companion Animal Pharmaceuticals Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Companion Animal Pharmaceuticals Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Companion Animal Pharmaceuticals Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. ESG Analysis of Market Leaders

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

• 17.1. Technology Analysis

18. Regulatory Framework and Innovation

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Zoetis Services LLC.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Merck & Co., Inc.
  • 20.3.3. Boehringer Ingelheim International GmbH
  • 20.3.4. Elanco
  • 20.3.5. Virbac
  • 20.3.6. Ceva
  • 20.3.7. Vetoquinol
  • 20.3.8. Dechra Pharmaceuticals PLC
  • 20.3.9. Orion Group Holdings, Inc.
  • 20.3.10. Neogen Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer